This website is intended for a health professional readership
Ameratunga R, Lehnert K, Leung E, et al. Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection. NZ Med J 2020;133(1515):112–18.
GALVUS and GALVUMET remain an effective, subsidised treatment strategy for your type 2 diabetes patient not reaching their HbA1c target1-3
New Zealand Doctor